ALDX vs. TSVT, XBIT, FHTX, IMMP, RENB, ME, PBYI, ACIU, CDT, and AQST
Should you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include 2seventy bio (TSVT), XBiotech (XBIT), Foghorn Therapeutics (FHTX), Immutep (IMMP), Renovaro (RENB), 23andMe (ME), Puma Biotechnology (PBYI), AC Immune (ACIU), Conduit Pharmaceuticals (CDT), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical preparations" industry.
Aldeyra Therapeutics (NASDAQ:ALDX) and 2seventy bio (NASDAQ:TSVT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations, community ranking and media sentiment.
Aldeyra Therapeutics has higher earnings, but lower revenue than 2seventy bio. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than 2seventy bio, indicating that it is currently the more affordable of the two stocks.
Aldeyra Therapeutics has a net margin of 0.00% compared to 2seventy bio's net margin of -216.73%. Aldeyra Therapeutics' return on equity of -24.69% beat 2seventy bio's return on equity.
Aldeyra Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, 2seventy bio has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500.
Aldeyra Therapeutics currently has a consensus target price of $9.33, suggesting a potential upside of 124.90%. 2seventy bio has a consensus target price of $13.17, suggesting a potential upside of 165.99%. Given 2seventy bio's higher possible upside, analysts clearly believe 2seventy bio is more favorable than Aldeyra Therapeutics.
In the previous week, Aldeyra Therapeutics had 3 more articles in the media than 2seventy bio. MarketBeat recorded 6 mentions for Aldeyra Therapeutics and 3 mentions for 2seventy bio. Aldeyra Therapeutics' average media sentiment score of 0.57 beat 2seventy bio's score of 0.34 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.
Aldeyra Therapeutics received 457 more outperform votes than 2seventy bio when rated by MarketBeat users. Likewise, 69.46% of users gave Aldeyra Therapeutics an outperform vote while only 58.97% of users gave 2seventy bio an outperform vote.
59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 93.9% of 2seventy bio shares are held by institutional investors. 7.3% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 2.6% of 2seventy bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Aldeyra Therapeutics beats 2seventy bio on 11 of the 16 factors compared between the two stocks.
Get Aldeyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aldeyra Therapeutics Competitors List
Related Companies and Tools
